Return to site

The global Epigenetics Market is projected to grow at a CAGR of 13.3%

The global epigenetics market is projected to reach USD 1.60 billion by 2022

· Biotechnology,Healthcare,Pharmaceuticals
epigenetics-market

Epigenetics Market by Product (Modifying Enzymes, DNA Polymerase, Acetylase, Methyltransferase, Instruments & Consumables, Kit, Bisulphite Conversion Kit, Reagents), by Research Area (Developmental Biology, Oncology)–Global Forecast to 2020

Epigenetics refers to the covalent modification of DNA, RNA, or protein that result in changes to the function and/or regulation of these molecules, without altering their primary sequences. Epigenetics has its applications in large number of fields including oncology, drug discovery, disease diagnosis, developmental biology and plant sciences. It is one of the most widely used techniques for cancer biomarkers discovery and development. According to GLOBOCON, 2012 prevalence of cancer is growing. For instance, there were 14.1 million new cancer cases, 8.2 million cancer deaths, and 32.6 million people living with cancer (within five years of diagnosis) in 2012 globally. A high prevalence of cancer will majorly drive the epigenetics market. Furthermore, factors such as an increasing research activities and R&D funding by private and government organizations will also aid to the growth of this market.

The research areas segment of epigenetics will be an important revenue pockets during the forecast period (2015–2020). By research areas, the market is divided into oncology, developmental biology, drug discovery and other epigenetics research areas. Drug discovery segment is expected to grow at a higher rate during the forecast period. The emerging markets like Brazil, Russia, India and China provide potential growth opportunities for the growth of the global epigenetics market.

North America is expected to account for the largest share of the global epigenetics market in 2015. However, the Asian market is expected to grow at the highest rate during the forecast period and represents the new revenue pockets for the epigenetics market. According to the Battelle (an R&D magazine), at the current rates of growth and investment, China’s total funding of R&D is expected to surpass that of the U.S. by about 2022.

All Posts
×

Almost done…

We just sent you an email. Please click the link in the email to confirm your subscription!

OKSubscriptions powered by Strikingly